Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells

Science Signaling

Volumn 9, Issue 447, 2016, Pages

  Li, Haiyan S ^a   Liu, Chengwen ^a   Xiao, Yichuan ^a   Chu, Fuliang ^a   Liang, Xiaoxuan ^a   Peng, Weiyi ^a   Hu, Jianhua ^a   Neelapu, Sattva S ^a   Sun, Shao Cong ^a,b   Hwu, Patrick ^a,b   Watowich, Stephanie S ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR DENDRITIC CELL VACCINE; INHIBITOR OF DIFFERENTIATION 2; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; IDB2 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC CODE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GENE; TUMOR IMMUNITY; ANIMAL; CELLULAR IMMUNITY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; IMMUNITY, CELLULAR; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MELANOMA; MICE; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84989246345     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaf3957     Document Type: Article

References (69)

1. S. Anguille, E. L. Smits, E. Lion, V. F. van Tendeloo, Z. N. Berneman, Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257-e267 (2014).
2. K. J. Radford, K. M. Tullett, M. H. Lahoud, Dendritic cells and cancer immunotherapy. Curr. Opin. Immunol. 27, 26-32 (2014).
3. J. Helft, J. Böttcher, P. Chakravarty, S. Zelenay, J. Huotari, B. U. Schraml, D. Goubau, C. Reis e Sousa, GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells. Immunity 42, 1197-1211 (2015).
4. G. Dranoff, GM-CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002).
5. K. Palucka, J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38-48 (2013).
6. E. A. Mittendorf, G. T. Clifton, J. P. Holmes, E. Schneble, D. van Echo, S. Ponniah, G. E. Peoples, Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann. Oncol. 25, 1735-1742 (2014).
7. E. J. Lipson, W. H. Sharfman, S. Chen, T. L. McMiller, T. S. Pritchard, J. T. Salas, S. Sartorius-Mergenthaler, I. Freed, S. Ravi, H.Wang, B. Luber, J. D. Sproul, J. M. Taube, D. M. Pardoll, S. L. Topalian, Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med. 13, 214 (2015).
8. E. Daro, B. Pulendran, K. Brasel, M. Teepe, D. Pettit, D. H. Lynch, D. Vremec, L. Robb, K. Shortman, H. J. McKenna, C. R. Maliszewski, E. Maraskovsky, Polyethylene glycolmodified GM-CSF expands CD11bhighCD11chigh but notCD11blowCD11chigh murine dendritic cells in vivo: A comparative analysis with Flt3 ligand. J. Immunol. 165, 49-58 (2000).
9. G. Miller, V. G. Pillarisetty, A. B. Shah, S. Lahrs, Z. Xing, R. P. DeMatteo, Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-Term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J. Immunol. 169, 2875-2885 (2002).
10. Y. Zhan, E. M. Carrington, A. van Nieuwenhuijze, S. Bedoui, S. Seah, Y. Xu, N. Wang, J. D. Mintern, J. A. Villadangos, I. P. Wicks, A. M. Lew, GM-CSF increases crosspresentation and CD103 expression by mouse CD8+ spleen dendritic cells. Eur. J. Immunol. 41, 2585-2595 (2011).
11. P. Sathe, J. Pooley, D. Vremec, J. Mintern, J.-O. Jin, L.Wu, J.-Y. Kwak, J. A. Villadangos, K. Shortman, The acquisition of antigen cross-presentation function by newly formed dendritic cells. J. Immunol. 186, 5184-5192 (2011).
12. S. Bedoui, P. G. Whitney, J. Waithman, L. Eidsmo, L. Wakim, I. Caminschi, R. S. Allan, M. Wojtasiak, K. Shortman, F. R. Carbone, A. G. Brooks, W. R. Heath, Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10, 488-495 (2009).
13. S. Henri, L. F. Poulin, S. Tamoutounour, L. Ardouin, M. Guilliams, B. de Bovis, E. Devilard, C. Viret, H. Azukizawa, A. Kissenpfennig, B. Malissen, CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207, 189-206 (2010).
14. J. T. Jackson, Y. Hu, R. Liu, F. Masson, A. DAmico, S. Carotta, A. Xin, M. J. Camilleri, A. M. Mount, A. Kallies, L. Wu, G. K. Smyth, S. L. Nutt, G. T. Belz, Id2 expression delineates differential checkpoints in the genetic program of CD8a+ and CD103+ dendritic cell lineages. EMBO J. 30, 2690-2704 (2011).
15. M. Greter, J. Helft, A. Chow, D. Hashimoto, A. Mortha, J. Agudo-Cantero, M. Bogunovic, E. L. Gautier, J. Miller, M. Leboeuf, G. Lu, C. Aloman, B. Brown, J. W. Pollard, H. Xiong, G. Randolph, J. Chipuk, P. S. Frenette, M. Merad, GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031-1046 (2012).
16. H. S. Li, C. Y. Yang, K. C. Nallaparaju, H. Zhang, Y.-J. Liu, A. W. Goldrath, S. S.Watowich, The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood 120, 4363-4373 (2012).
17. M. L. Broz, M. Binnewies, B. Boldajipour, A. E. Nelson, J. L. Pollack, D. J. Erle, A. Barczak, M. D. Rosenblum, A. Daud, D. L. Barber, S. Amigorena, L. J. vant Veer, A. I. Sperling, D. M. Wolf, M. F. Krummel, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638-652 (2014).
18. S. Spranger, R. Bao, T. F. Gajewski, Melanoma-intrinsic b-catenin signalling prevents anti-Tumour immunity. Nature 523, 231-235 (2015).
19. G. T. Belz, S. L. Nutt, Transcriptional programming of the dendritic cell network. Nat. Rev. Immunol. 12, 101-113 (2012).
20. H. S. Li, S. S. Watowich, Diversification of dendritic cell subsets: Emerging roles for STAT proteins. JAKSTAT 2, e25112 (2013).
21. C. Hacker, R. D. Kirsch, X.-S. Ju, T. Hieronymus, T. C. Gust, C. Kuhl, T. Jorgas, S. M. Kurz, S. Rose-John, Y. Yokota, M. Zenke, Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4, 380-386 (2003).
22. F. Ginhoux, K. Liu, J. Helft, M. Bogunovic, M. Greter, D. Hashimoto, J. Price, N. Yin, J. Bromberg, S. A. Lira, E. R. Stanley, M. Nussenzweig, M. Merad, The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206, 3115-3130 (2009).
23. B. L. Kee, E and ID proteins branch out. Nat. Rev. Immunol. 9, 175-184 (2009).
24. B. Cisse, M. L. Caton, M. Lehner, T. Maeda, S. Scheu, R. Locksley, D. Holmberg, C. Zweier, N. S. den Hollander, S. G. Kant, W. Holter, A. Rauch, Y. Zhuang, B. Reizis, Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 135, 37-48 (2008).
25. G. T. Motz, G. Coukos, Deciphering and reversing tumor immune suppression. Immunity 39, 61-73 (2013).
26. M.Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé, W. G. Kerr, R. Jove, D. Pardoll, H. Yu, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005).
27. H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
28. M. Kortylewski, H. Xin, M. Kujawski, H. Lee, Y. Liu, T. Harris, C. Drake, D. Pardoll, H. Yu, Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123 (2009).
29. T. Iwata-Kajihara, H. Sumimoto, N. Kawamura, R. Ueda, T. Takahashi, H. Mizuguchi, M. Miyagishi, K. Takeda, Y. Kawakami, Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J. Immunol. 187, 27-36 (2011).
30. Y. Ma, G. V. Shurin, Z. Peiyuan, M. R. Shurin, Dendritic cells in the cancer microenvironment. J. Cancer 4, 36-44 (2013).
31. T. Wang, G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. Pardoll, H. Yu, Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004).
32. L. Wang, T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, H. Yu, IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464 (2009).
33. X.-P. Yang, K. Ghoreschi, S. M. Steward-Tharp, J. Rodriguez-Canales, J. Zhu, J. R. Grainger, K. Hirahara, H.-W. Sun, L. Wei, G. Vahedi, Y. Kanno, J. J. OShea, A. Laurence, Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247-254 (2011).
34. E. Lázár-Molnár, H. Hegyesi, S. Tóth, A. Falus, Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12, 547-554 (2000).
35. E. Esashi, Y.-H. Wang, O. Perng, X.-F. Qin, Y.-J. Liu, S. S. Watowich, The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28, 509-520 (2008).
36. J. A. Melillo, L. Song, G. Bhagat, A. B. Blazquez, C. R. Plumlee, C. Lee, C. Berin, B. Reizis, C. Schindler, Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 184, 2638-2645 (2010).
37. H. Assi, J. Espinosa, S. Suprise, M. Sofroniew, R. Doherty, D. Zamler, P. R. Lowenstein, M. G. Castro, Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM. PLOS ONE 9, e96318 (2014).
38. E. Zandi, M. Karin, Bridging the gap: Composition, regulation, and physiological function of the IkB kinase complex. Mol. Cell. Biol. 19, 4547-4551 (1999).
39. K. M. Murphy, A. B. Heimberger, D. Y. Loh, Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250, 1720-1723 (1990).
40. X. Chen, M. Bäumel, D. N. Männel, O. M. Z. Howard, J. J. Oppenheim, Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179, 154-161 (2007).
41. X. Chen, X. Wu, Q. Zhou, O. M. Z. Howard, M. G. Netea, J. J. Oppenheim, TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. J. Immunol. 190, 1076-1084 (2013).
42. M. Sade-Feldman, J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, M. Baniyash, Tumor necrosis factor-A blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38, 541-554 (2013).
43. A. O. Kamphorst, R. Ahmed, CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy 5, 975-987 (2013).
44. A. H. Sharpe, E. J. Wherry, R. Ahmed, G. J. Freeman, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239-245 (2007).
45. P. Sharma, J. P. Allison, Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205-214 (2015).
46. W. H. Fridman, F. Pagès, C. Sautès-Fridman, J. Galon, The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
47. J. L. Hor, P. G. Whitney, A. Zaid, A. G. Brooks, W. R. Heath, S. N. Mueller, Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection. Immunity 43, 554-565 (2015).
48. Y. Nefedova, S. Nagaraj, A. Rosenbauer, C. Muro-Cacho, S. M. Sebti, D. I. Gabrilovich, Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-Activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525-9535 (2005).
49. P. Cheng, C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, J. Roth, D. I. Gabrilovich, Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
50. N. Sonda, M. Chioda, S. Zilio, F. Simonato, V. Bronte, Transcription factors in myeloidderived suppressor cell recruitment and function. Curr. Opin. Immunol. 23, 279-285 (2011).
51. H. Zhang, H. Hu, N. Greeley, J. Jin, A. J. Matthews, E. Ohashi, M. S. Caetano, H. S. Li, X. Wu, P. K. Mandal, J. S. McMurray, S. J. Moghaddam, S.-C. Sun, S. S. Watowich, STAT3 restrains RANK-And TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat. Commun. 5, 5798 (2014).
52. D. Sancho, D. Mourão-Sá, O. P. Joffre, O. Schulz, N. C. Rogers, D. J. Pennington, J. R. Carlyle, C. Reis e Sousa, Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-Type lectin. J. Clin. Invest. 118, 2098-2110 (2008).
53. J. Idoyaga, A. Lubkin, C. Fiorese, M. H. Lahoud, I. Caminschi, Y. Huang, A. Rodriguez, B. E. Clausen, C. G. Park, C. Trumpfheller, R. M. Steinman, Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. U.S.A. 108, 2384-2389 (2011).
54. A. Herrmann, S. J. Priceman, P. Swiderski, M. Kujawski, H. Xin, G. A. Cherryholmes, W. Zhang, C. Zhang, C. Lahtz, C. Kowolik, S. J. Forman, M. Kortylewski, H. Yu, CTLA4 aptamer delivers STAT3 siRNA to tumor-Associated and malignant T cells. J. Clin. Invest. 124, 2977-2987 (2014).
55. D. M. S. Hossain, S. K. Pal, D. Moreira, P. Duttagupta, Q. Zhang, H. Won, J. Jones, M. DApuzzo, S. Forman, M. Kortylewski, TLR9-Targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin. Cancer Res. 21, 3771-3782 (2015).
56. K. Hildner, B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, R. D. Schreiber, T. L. Murphy, K. M. Murphy, Batf3 deficiency reveals a critical role for CD8a+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
57. B. T. Edelson, W. KC, R. Juang, M. Kohyama, L. A. Benoit, P. A. Klekotka, C. Moon, J. C. Albring, W. Ise, D. G. Michael, D. Bhattacharya, T. S. Stappenbeck, M. J. Holtzman, S.-S. J. Sung, T. L. Murphy, K. Hildner, K. M. Murphy, Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8a+ conventional dendritic cells. J. Exp. Med. 207, 823-836 (2010).
58. F. Masson, M. Ghisi, J. R. Groom, A. Kallies, C. Seillet, R. W. Johnstone, S. L. Nutt, G. T. Belz, Id2 represses E2A-mediated activation of IL-10 expression in T cells. Blood 123, 3420-3428 (2014).
59. B. Ruffell, D. Chang-Strachan, V. Chan, A. Rosenbusch, C. M. T. Ho, N. Pryer, D. Daniel, E. S. Hwang, H. S. Rugo, L. M. Coussens, Macrophage IL-10 blocks CD8+ T celldependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623-637 (2014).
60. K. Taniguchi, M. Karin, IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54-74 (2014).
61. R. Hamano, J. Huang, T. Yoshimura, J. J. Oppenheim, X. Chen, TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur. J. Immunol. 41, 2010-2020 (2011).
62. H. Nie, Y. Zheng, R. Li, T. B. Guo, D. He, L. Fang, X. Liu, L. Xiao, X. Chen, B. Wan, Y. E. Chin, J. Z. Zhang, Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-A in rheumatoid arthritis. Nat. Med. 19, 322-328 (2013).
63. Q. Zhang, F. Cui, L. Fang, J. Hong, B. Zheng, J. Z. Zhang, TNF-A impairs differentiation and function of TGF-b-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J. Mol. Cell Biol. 5, 85-98 (2013).
64. F. Kratochvill, G. Neale, J. M. Haverkamp, L.-A. Van de Velde, A. M. Smith, D. Kawauchi, J. McEvoy, M. F. Roussel, M. A. Dyer, J. E. Qualls, P. J. Murray, TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 12, 1902-1914 (2015).
65. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
66. M. H. Kershaw, J. A. Westwood, P. K. Darcy, Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525-541 (2013).
67. K. Takeda, T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, S. Akira, Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161, 4652-4660 (1998).
68. M. L. Caton, M. R. Smith-Raska, B. Reizis, Notch-RBP-J signaling controls the homeostasis of CD8-dendritic cells in the spleen. J. Exp. Med. 204, 1653-1664 (2007).
69. M. Uhlik, L. Good, G. Xiao, E. W. Harhaj, E. Zandi, M. Karin, S.-C. Sun, NF-kBinducing kinase and IkB kinase participate in human T-cell leukemia virus I Taxmediated NF-kB activation. J. Biol. Chem. 273, 21132-21136 (1998).